Abstract

Leprosy household contacts are generally more prone to develop the disease compared to the general population. Previous studies have demonstrated that genes related to the alternative activation (M2) profile in macrophages are associated with the increased bacillary load in multibacillary leprosy patients (MB), and that contacts of MB patients have a higher risk of contracting the disease. In addition, positive serological responses to PGL-1 or LID-1 are associated with a higher risk of disease. We performed a 5-year follow-up of contacts of leprosy patients and evaluated the pattern of gene and protein expression in cells from contacts that developed leprosy during this period. Leprosy household contacts had decreased soluble CD163 and heme oxygenase 1 (HO-1) serum levels when compared with healthy donors and leprosy patients. In contrast, arginase 1 activities were higher in contacts when compared with both healthy donors and leprosy patients. Of the contacts, 33 developed leprosy during the follow-up. Gene expression analysis revealed reduced ARG1 expression in these contacts when compared with contacts that did not develop disease. Arginase activity was a good predictive marker of protection in contacts (sensitivity: 90.0%, specificity: 96.77%) and the association with serology for anti-PGL-1 and anti-LID-1 increased the sensitivity to 100%. Altogether, the data presented here demonstrate a positive role of arginase against leprosy and suggest that the evaluation of arginase activity should be incorporated into leprosy control programs in order to aid in the decision of which contacts should receive chemoprophylaxis.

Details

Title
Arginase 1 is a marker of protection against illness in contacts of leprosy patients
Author
da Silva Prata Rhana Berto 1 ; Mendes, Mayara Abud 2 ; Soares, Vinicius Cardoso 3 ; França-Costa, Jaqueline 4 ; Sales, Anna Maria 2 ; Duppré, Nádia Cristina 2 ; de Matos Borges Valéria 5 ; da Silva Tatiana Pereira 2 ; Bozza, Patricia Torres 3 ; Bozza, Marcelo Torres 6 ; Sarno Euzenir Nunes 2 ; Moraes, Milton Ozório 2 ; Sperandio da Silva Gilberto Marcelo 7 ; Pinheiro, Roberta Olmo 2 

 Oswaldo Cruz Foundation, Leprosy Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931); Federal University of Rio de Janeiro, Inflammation and Immunity Laboratory, Rio de Janeiro, Brazil (GRID:grid.8536.8) (ISNI:0000 0001 2294 473X) 
 Oswaldo Cruz Foundation, Leprosy Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931) 
 Oswaldo Cruz Foundation, Immunopharmacology Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931) 
 Federal University of Bahia, Immunology Service, Professor Edgar Santos University Hospital, Salvador, Brazil (GRID:grid.8399.b) (ISNI:0000 0004 0372 8259); Oswaldo Cruz Foundation, Inflammation and Biomarkers Laboratory, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931) 
 Oswaldo Cruz Foundation, Inflammation and Biomarkers Laboratory, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931) 
 Federal University of Rio de Janeiro, Inflammation and Immunity Laboratory, Rio de Janeiro, Brazil (GRID:grid.8536.8) (ISNI:0000 0001 2294 473X) 
 Oswaldo Cruz Foundation, Clinical Research Laboratory in Chagas Disease, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2663154767
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.